研究关注：Roche secures CE mark for Alzheimer’s blood test

## 事件概览

Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 (pTau217) blood test designed to rule in and rule out amyl...

## 核心信息

Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 (pTau217) blood test designed to rule in and rule out amyloid pathology, a hallmark of Alzheimer's disease. Developed with Eli Lilly and Co., the test brings to the market another much-needed solution to help clinicians diagnose Alzheimer’s patients following the FDA approval of Fujirebio Diagnostics Inc.’s blood test last year.

## 为什么值得关注

这条内容与 neuroscience 相关，可能影响科研选题、技术趋势判断或产业观察。BioDir 已根据来源、摘要长度、主题词和潜在影响给出 39 分的候选评分。

## 发布提示

发布前应核对原文链接、研究对象、样本规模、方法限制和结论边界。若来源为 bioRxiv 或 medRxiv，应明确标注其为预印本，尚未经过同行评议。